Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Now available on-demand! Cracking the code: learnings from oligonucleotide method development WATCH NOW

PRA Health Sciences Bioanalytical Laboratories: Lenexa US, KS and Assen, The Netherlands

7 Mar 2018
General interest

At PRA Health Sciences, recognize that the world of clinical development is complex and dynamic, and we’ve designed our bioanalytical laboratories to meet those challenges. Proactive and always looking to the future, we provide the technology, innovative approaches, and high scientific standards required to deliver industry-leading laboratory services.

Click here to find out more about PRA Health Sciences

 

 

Top content

  • Air pollution’s hidden impact: linking fine particles to early signs of autoimmune disease

Related tags

bioanalysis laboratory PRA Health Sciences technology
Previous article

Related articles

22 JUN 2015 GENERAL INTEREST
Current and future bioanalytical approaches for stroke assessment
17 MAR 2020 EXPERT OPINION
COVID-19 low-cost and laboratory-safe detection protocol
7 MAR 2013 COLLABORATIONS AND MERGERS
Preterm birth risk diagnostic test to be given boost by partnership between Agilent Technologies and Sera PrognosticsPreterm birth risk diagnostic test to be given boost by partnership between Agilent Technologies and Sera Prognostics
7 FEB 2013 GENERAL INTEREST
Increased accessibility of next-generation sequencing?
19 FEB 2024 INTERVIEWS
Rapid generation of bispecific antibodies for high-throughput screening with SpyLock technology
25 JAN 2019 BIOANALYSIS RISING STAR AWARD
Bioanalysis Rising Star Award Judging Panel: Kim Haynes
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone